CA Patent

CA3021677C — Use of thyroid beta-agonists

Assigned to Viking Therapeutics Inc · Expires 2024-11-12 · 2y expired

What this patent protects

Methods useful for treating X-linked adrenoleukodystrophy are provided.

USPTO Abstract

Methods useful for treating X-linked adrenoleukodystrophy are provided.

Drugs covered by this patent

ketorolac-tromethamine (KETOROLAC TROMETHAMINE)

Patent Metadata

Patent number: CA3021677C
Jurisdiction: CA
Classification: —
Expires: 2024-11-12
Drug substance claim: No
Drug product claim: No
Assignee: Viking Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.